Decreased Docosahexaenoic Acid Levels in Serum of HIV Carrier Patients

Godoy, Guilherme; Antunes, Marina Masetto; Silva, Maria Angélica Raffaini Cóvas Pereira da; Fernandes, Ingrid de Lima; Visentainer, Jesuí Vergílio; Curi, Rui; Bazotte, Roberto Barbosa

doi:10.1089/jmf.2020.0119

Cited by 3 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…We also remember that the information obtained will be used only for research purposes and will be treated with confidentiality to preserve your privacy''. Therefore, sera from all HIV+ patients under ART 14,15 were used. Data concerning inclusion and exclusion criteria, age, gender, medical history, educational level, time with AIDS, therapeutic approach for ART, lifestyle, biochemical, toxicological, hematological, and inflammatory parameters can be found in our previous studies.…”

Section: Cohort Selection and Patient Treatmentmentioning

confidence: 99%

“…Data concerning inclusion and exclusion criteria, age, gender, medical history, educational level, time with AIDS, therapeutic approach for ART, lifestyle, biochemical, toxicological, hematological, and inflammatory parameters can be found in our previous studies. 14,15 The patients enrolled in this study were from the Public Service Health Care for Sexually Transmitted Diseases/AIDS Center of Maringa ´City, Parana ´, Brazil, in the period of 2012-2015. Our initial cohort included 2534 HIV+ patients treated with ART.…”

Section: Cohort Selection and Patient Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Metabolite variations in the sera of HIV+ patients after an oral administration of effervescent glutamine and in comparison to non-HIV individuals by NMR

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Cohort Selection and Patient Treatmentmentioning

confidence: 99%

Section: Cohort Selection and Patient Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Metabolite variations in the sera of HIV+ patients after an oral administration of effervescent glutamine and in comparison to non-HIV individuals by NMR

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Increased DHA consumption can reduce the risk of depression, schizophrenia, bipolar disorder, and other brain disorders in different populations (17)(18)(19). Moreover, previous studies showed that the level of DHA was decreased in the blood of HIV-infected patients (20). Nonetheless, it remains to be investigated whether DHA supplementation can change the cognitive status of HIV-infected patients.…”

Section: Introductionmentioning

confidence: 99%

Effects of Docosahexanoic Acid on Gut Microbiota and Fecal Metabolites in HIV-Infected Patients With Neurocognitive Impairment: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial

et al. 2022

View full text Add to dashboard Cite

Neurocognitive impairment (NCI) and gut microbiota dysbiosis are prevalent in patients with HIV infection. Docosahexanoic acid (DHA) supplementation may alleviate multiple neurocognitive diseases symptoms and plays important role in regulating gut microbiota. However, it is not known whether DHA algae oil supplements can alleviate neurocognitive impairment (NCI) and regulate gut microbiota and fecal metabolites. A randomized, double-blind, placebo-controlled trial was performed on 68 HIV-infected patients with NCI. Participants were randomized to receive a 3.15 g daily DHA algae oil supplement or placebo for 6 months. We collected blood and fecal samples from these patients before and after the trial. Mini mental state examination (MMSE) and neuropsychological tests (NP tests) were administered to assess the cognitive status of participants. The influence of DHA algae oil on the gut microbiota, fecal metabolomics, plasma proinflammatory, and oxidative stress factors was also investigated. There were no significant changes in NCI according to global diagnosis score (GDS) and MMSE score within the two groups, while patients receiving DHA had improvement in several blood lipids, pro-inflammatory and oxidative stress factors. The DHA supplement increased α-diversity indexes, increased abundances of Blautia, Bifidobacterium, Dorea, Lactobacillus, Faecalibacterium, Fusobacterium, and Agathobacter, and decreased abundances of Bacteroides and Prevotella_9. Furthermore, DHA supplement was correlated with improved fecal lipid metabolites as indicated by ceramides, bile acids, glycerophospholipids. In addition, the DHA supplement was associated with altered cholesterol metabolism and purine metabolism pathways. A daily supplement of DHA algae oil for 6 months has been shown to promote favorable transformations in gut microbiota, profiles of fecal metabolomic, and factors responsible for proinflammatory and oxidative stress, which might be beneficial for the prognosis of HIV-infected patients with NCI in the long-term.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT04242004, identifier: NCT04242004.

show abstract

The Myristic Acid:Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid:n-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers

Antunes

Godoy

Curi

et al. 2022

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

Decreased Docosahexaenoic Acid Levels in Serum of HIV Carrier Patients

Cited by 3 publications

References 34 publications

Metabolite variations in the sera of HIV+ patients after an oral administration of effervescent glutamine and in comparison to non-HIV individuals by NMR

Metabolite variations in the sera of HIV+ patients after an oral administration of effervescent glutamine and in comparison to non-HIV individuals by NMR

Effects of Docosahexanoic Acid on Gut Microbiota and Fecal Metabolites in HIV-Infected Patients With Neurocognitive Impairment: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial

The Myristic Acid:Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid:n-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers

Contact Info

Product

Resources

About